...
首页> 外文期刊>Functional Foods In Health And Disease >Effects of probiotics and synbiotic on lipid profiles in adults at risk of type 2 diabetes: A double-blind randomized controlled clinical trial
【24h】

Effects of probiotics and synbiotic on lipid profiles in adults at risk of type 2 diabetes: A double-blind randomized controlled clinical trial

机译:益生菌和合生元对有2型糖尿病风险的成年人脂质分布的影响:一项双盲随机对照临床试验

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: The use of probiotics and/or prebiotics as an effective means of regulating gut microbiota may have a beneficial effect on metabolic disorders.Aims: This study was designed to assess the ability of probiotics and synbiotic to modify lipid profiles in subjects with prediabetes who are at risk of diabetes and cardiovascular diseases.Methods: In a randomized double-blind placebo-controlled clinical trial, 120 pre-diabetic adults aged 35-70 years from the first-degree family of type 2 diabetic patients were recruited and randomly equally assigned to consume 6 g/d either probiotic or synbiotic or placebo supplements for 6 months. The probiotics used were Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, and Bifidobacterium longum. Food record, physical activity, anthropometric measures and lipid profiles were assessed repeatedly at baseline, and 3- and 6- month supplementation.Results: Probiotics and synbiotic were effective in reduction of serum triglycerides after 6 months of intervention (SMD=- 10.6 and -9.4 respectively). Compared with the placebo, synbiotic resulted in a significant reduction in serum triglyceride levels (MD±SE: -9.4 ± 6.6 mg/dl vs. +13.2±6.8 mg/dl, p=0.02). Serum total-, LDL-, and HDL-cholesterol were statistically unaffected by probiotic or synbiotic.Conclusion: The results of this study showed that supplementation with probiotic and especially synbiotic could decrease the concentration of triglyceride in prediabetic adults. This finding could warrant future studies to determine the therapeutic and preventive effects of these supplements in individuals at risk of diabetes and cardiovascular diseases.Iranian Registry of Clinical Trials: IRCT201511032321N2. Date registered: February 27, 2016.
机译:背景:益生菌和/或益生元作为调节肠道菌群的有效手段可能对代谢紊乱具有有益的作用。目的:本研究旨在评估益生菌和合生元对患有糖尿病的糖尿病前期受试者的脂质分布的影响。方法:在一项随机的双盲安慰剂对照临床试验中,招募了120名来自2型糖尿病患者一级家庭的35-70岁的糖尿病前成年人,并进行了均等分配每天服用6克/天的益生菌或合生元或安慰剂补充剂。所用的益生菌是嗜酸乳杆菌,双歧双歧杆菌,乳酸双歧杆菌和长双歧杆菌。在基线,补充3个月和6个月时反复评估食物记录,体力活动,人体测量学和血脂状况。结果:益生菌和合生元在干预6个月后可有效降低血清甘油三酯(SMD =-10.6和- 9.4)。与安慰剂相比,合生素可显着降低血清甘油三酯水平(MD±SE:-9.4±6.6 mg / dl与+ 13.2±6.8 mg / dl,p = 0.02)。血清总胆固醇,低密度脂蛋白胆固醇和高密度脂蛋白胆固醇在统计学上不受益生菌或合生元的影响。结论:本研究结果表明,补充益生菌,尤其是合生元可以降低糖尿病前成年人中甘油三酸酯的浓度。这一发现可能值得进行进一步的研究,以确定这些补充剂对患有糖尿病和心血管疾病风险的个体的治疗和预防作用。伊朗临床试验注册处:IRCT201511032321N2。注册日期:2016年2月27日。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号